Drug intelligence / Profile preview

SK-08

Development stage: Unknown
Lead developer: Consun Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

SK-08 is a **Category 1 chemical drug** developed for the treatment of **chronic kidney disease (CKD)**. It is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy participants. The drug is being tested in single ascending doses (5 mg to 60 mg) in a double-blind, placebo-controlled, dose-escalation design. The development aims to address significant unmet clinical needs in CKD, a chronic progressive disease with abnormal kidney structure or function. The specific molecular mechanism of action and molecular targets have not been disclosed publicly as of July 2025[1][3][4][2][8][5][10].

Brand names: SK-08SK08SK 08
Other names: SK-08 TabletSK08 TabletSK 08 Tablet

Targets

sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on SK-08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK-08.

Explore the full profile